Growth and functional differentiation of the liver are critical to late gestation fetal metabolism, the perinatal transition and metabolic adaptation by the newborn. The biology of fetal liver development also has implications for regulation of fetal somatic growth, hepatic carcinogenesis, and cell-based therapy for liver disease. Our laboratory has long focused on late gestation liver development in the rodent. In doing so, we have identified a fetal hepatocyte phenotype that is defined by the signaling pathways that regulate fetal hepatocyte growth, proliferation and gene expression. More recently, we demonstrated the ability of late gestation fetal rat liver cells possessing a key hepatocyte marker, leucine amino peptidase (LAP), to repopulate an injured adult liver. This is a capacity not shared by adult rat hepatocytes. The present proposal is based on the central hypothesis that histone variants and histone posttranslational modifications (PTMs), acting through effects on chromatin structure, account for the signaling phenotype of late gestation fetal rat hepatocytes and the persistence of this phenotype following transplantation into the adult liver microenvironment. The long term goal of the project is to identify genetic and epigenetic mechanisms that account for the novel characteristics of fetal liver cells, thereby applying an understanding of fetal liver development o the development of cell-based therapy for liver disease. This goal will be pursued through three Specific Aims.
Specific Aim 1 is to identify a fetal hepatocyte epigenetic signature by examining chromatin structure, histone variants and histone PTMs in liver during late fetal versus adult life Specific Aim 2 is to characterize the functional relationship between histone variants, histone PTMs, chromatin structure and regulation of key growth-regulating genes in liver during the fetal to adult transition.
This aim will test the hypothesis that specific histone variants and PTMs are associated with developmental changes in critical growth-regulating genes.
In Specific Aim 3, we will assess the role of the epigenetic signature identified in Aims 1 and 2 in defining and maintaining the ability of late gestation fetal rat liver cells to repopulate an injured adult rat iver.
This aim will test the hypothesis that a fetal hepatic epigenetic signature is characteristic of a subpopulation of fetal hepatocytes that possess both hepatocyte and bile ductular markers, and that this epigenetic signature is present both before transplantation and after engraftment. Completion of these aims will provide insight into molecular mechanisms that determine cell behavior in the developing liver while advancing the development of cell-based therapy for liver disease. The project is innovative in a number of aspects. We will generate new information regarding the epigenetic regulation of gene expression during liver development. In doing so, we will characterize a previously unidentified, multipotent cell population in fetal liver that can repopulate an injured adult liver. Finally, we will use innovative methods throughout these studies, thus advancing the ability to study epigenetic regulation in the context of mammalian developmental physiology.

Public Health Relevance

The studies proposed in this application are aimed at defining molecular mechanisms that determine the behavior of fetal liver cells. This is of particular importance because these cells have the ability to repopulate an injured liver in an adult animal. The proposed studies will further our understanding of fetal liver development. This area has implications not only for the normal development of the liver, but also for the development of cell-based therapy for a spectrum of liver diseases for which there is, at present, no curative therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK100301-03
Application #
9022472
Study Section
Pregnancy and Neonatology Study Section (PN)
Program Officer
Burgess-Beusse, Bonnie L
Project Start
2014-05-01
Project End
2018-02-28
Budget Start
2016-03-01
Budget End
2017-02-28
Support Year
3
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Rhode Island Hospital
Department
Type
DUNS #
075710996
City
Providence
State
RI
Country
United States
Zip Code
Gruppuso, Philip A; Boylan, Joan M; Zabala, Valerie et al. (2018) Stability of histone post-translational modifications in samples derived from liver tissue and primary hepatic cells. PLoS One 13:e0203351
Sanders, Jennifer A (2017) Late Gestation Fetal Hepatocytes for Liver Repopulation in the Rat. Methods Mol Biol 1506:45-60
Boylan, Joan M; Francois-Vaughan, Heather; Gruppuso, Philip A et al. (2017) Engraftment and Repopulation Potential of Late Gestation Fetal Rat Hepatocytes. Transplantation 101:2349-2359
Adebayo Michael, Adeola O; Ahsan, Nagib; Zabala, Valerie et al. (2017) Proteomic analysis of laser capture microdissected focal lesions in a rat model of progenitor marker-positive hepatocellular carcinoma. Oncotarget 8:26041-26056
Tan, Ek Khoon; Shuh, Maureen; Francois-Vaughan, Heather et al. (2017) Negligible Oval Cell Proliferation Following Ischemia-Reperfusion Injury With and Without Partial Hepatectomy. Ochsner J 17:31-37
Francois-Vaughan, Heather; Adebayo, Adeola O; Brilliant, Kate E et al. (2016) Persistent effect of mTOR inhibition on preneoplastic foci progression and gene expression in a rat model of hepatocellular carcinoma. Carcinogenesis 37:408-419
Gruppuso, Philip A; Sanders, Jennifer A (2016) Regulation of liver development: implications for liver biology across the lifespan. J Mol Endocrinol 56:R115-25
Huse, Susan M; Gruppuso, Philip A; Boekelheide, Kim et al. (2015) Patterns of gene expression and DNA methylation in human fetal and adult liver. BMC Genomics 16:981
Boylan, Joan M; Sanders, Jennifer A; Neretti, Nicola et al. (2015) Profiling of the fetal and adult rat liver transcriptome and translatome reveals discordant regulation by the mechanistic target of rapamycin (mTOR). Am J Physiol Regul Integr Comp Physiol 309:R22-35